GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Slc2a4 | multiple interactions | ISO | SLC2A4 (Homo sapiens) | 6480464 | CTD | [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC2A4 mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone co-treated with 4,4'-hexafluorisopropylidene diphenol] results in increased expression of SLC2A4 mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of SLC2A4 mRNA; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SLC2A4 protein; Dichlorodiphenyl Dichloroethylene promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC2A4 mRNA] | PMID:19186324 PMID:26200599 PMID:31596606 PMID:33836827 | Slc2a4 | multiple interactions | ISO | Slc2a4 (Mus musculus) | 6480464 | CTD | [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC2A4 mRNA; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] | PMID:27605626 PMID:28285642 PMID:30665118 PMID:31009676 PMID:34302803 | |
Go Back to source page | Continue to Ontology report |